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Abstract
While metabolomics has tremendous potential for diagnostic biomarker and therapeutic target discovery, its utility may be
diminished by the variability that occurs due to environmental exposures including diet and the influences of the human
circadian rhythm. For successful translation of metabolomics findings into the clinical setting, it is necessary to exhaustively
define the sources of metabolome variation. To address these issues and to measure the variability of urinary and plasma
metabolomes throughout the day, we have undertaken a comprehensive inpatient study in which we have performed non-
targeted metabolomics analysis of blood and urine in 26 volunteers (13 healthy subjects with no known disease and 13
healthy subjects with autosomal dominant polycystic kidney disease not taking medication). These individuals were
evaluated in a clinical research facility on two separate occasions, over three days, while on a standardized, weight-based
diet. Subjects provided pre- and post-prandial blood and urine samples at the same time of day, and all samples were
analyzed by ‘‘fast lane’’ LC-MS-based global metabolomics. The largest source of variability in blood and urine metabolomes
was attributable to technical issues such as sample preparation and analysis, and less variability was due to biological
variables, meals, and time of day. Higher metabolome variability was observed after the morning as compared to the
evening meal, yet day-to-day variability was minimal and urine metabolome variability was greater than that of blood. Thus
we suggest that blood and urine are suitable biofluids for metabolomics studies, though nontargeted mass spectrometry
alone may not offer sufficient precision to reveal subtle changes in the metabolome. Additional targeted analyses may be
needed to support the data from nontargeted mass spectrometric analyses. In light of these findings, future metabolomics
studies should consider these sources of variability to allow for appropriate metabolomics testing and reliable clinical
translation of metabolomics data.
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Introduction
Of the growing number of omics techniques in current use in
basic and clinical science, metabolomics is most closely related to
organismal phenotype [1,2]. With this technique, all of the
metabolites produced endogenously (and sometimes exogenously)
in a living organism are analyzed in order to ascertain the internal
biochemical and metabolic processes taking place, such that
insights regarding normal physiology and pathophysiology can be
gleaned. To date, there have been many inroads using
metabolomics in medicine, such that the field is now poised to
discover clinically useful biomarkers and therapeutic targets in
nephrology, cancer, and other medical fields (reviewed in [2–4]).
However, despite these advances, a healthy dose of caution is
required with respect to clinical translation in light of some widely
publicized premature attempts (discussed in [5]). Given the
relatively recent and rapid proliferation of clinical human studies
on metabolomics, it is essential that due diligence be considered
with regard to the terms of limitations of data interpretation, such
that future studies, and their conclusions, as well as clinical
applications are robust, reproducible, reliable and informative. For
a single (or a suite of) metabolite biomarker(s) to be useful as a
diagnostic or prognostic screening tool, its variability as a function
of time of day, dietary exposure, exercise, medication use, smoke
exposure and other exogenous stimuli needs to be established and
quantified such that interpretation of the data is reliable and
accurate. For example, one would not like to perform a cancer
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biomarker study only to find that what is identified as a
metabolomics signal is a function of time after a meal or due to
a medication exposure, rather than as a result of the underlying
biology of the cancer of interest [6].
While there have been several human and animal studies
attempting to address these issues, there have been very few
evaluations of metabolome variability in human subjects under
tightly controlled conditions in clinical settings [7,8], and even
fewer studies have evaluated all relevant parameters concurrently
in both blood and urine [7]. While there have been attempts to
evaluate normal individual metabolomes [9,10] demonstrating the
presence of personal metabolomic phenotypes [11], there have
been no published studies analyzing the sources of variability
utilizing blood and urine in an inpatient environment in the setting
of a chronic stable disease. In addition, most of the available
studies on diet and metabolomics have focused on the effects of a
specific dietary intervention [12–14] rather than time-of-day or
day-to-day variability. Therefore the present study was undertaken
utilizing healthy volunteer subjects (half with a chronic stable
hereditary kidney disorder) who were admitted to an inpatient
clinical research center and given standardized meals with regard
to calorie and carbohydrate intake at a consistent time of day while
blood and urine samples were obtained under uniform conditions
at specific times. Following sample procurement, samples were
handled in standardized fashion for both urine and blood samples,
and metabolomics data were subjected to rigorous statistical
evaluation. An extensive analysis of the data was performed to
identify intrinsic sources of variability as well as the nature of the
mealtime and temporal changes that occur within these two
readily accessible biofluids. Incorporating these findings into future
blood and urine based metabolomics studies will lead to
considerably sounder study conclusions.
Materials and Methods
Ethics statement
The study was approved by the Institutional Review Boards
both at Emory University and at the University of California,
Davis. All participants gave written informed consent.
Subject enrollment
To qualify for the study, participants had to be without any
medical condition (with the exception of ADPKD in that cohort),
not be taking any prescription medications or over the counter
medications within two weeks of study; and for women, have
regular menstrual cycles or be post-menopausal. In addition, all
clinical laboratory analyses including measurement of hematopoi-
etic and kidney function were required to be within normal limits.
Thirteen healthy volunteers and 13 subjects diagnosed with
ADPKD according to the Pei et al criteria [15] (Table S1) were
recruited and admitted to the inpatient unit of the Clinical
Research Network (CRN) of the Atlanta Clinical and Transla-
tional Science Institute at Emory University Hospital. Subjects did
not take prescription or over the counter medications for a
minimum of 2 weeks prior to study with the exception of one
subject, who had taken St. John’s Wort, vitamin E and black
cohosh within one day of evaluation. All female subjects who were
menstruating were evaluated in the follicular phase of the
menstrual cycle to eliminate variability related to post-ovulatory
changes. All subjects were interviewed by the research dietician of
the CRN and weighed. Based on the subject food preferences and
allergies a standardized test meal was developed by the Bionutri-
tion unit of the Clinical Research Network (CRN) that provided
similar calories as a function of body weight with breakfast, lunch,
and dinner, each prepared in identical fashion for each day of
testing. The 24-hour calorie intake prescribed was 2,500 kcal/kg/
day and 1.1 g/kg/day protein intake. Subjects were admitted to
the CRN for two days of testing (Days 1 and 2) and on a separate
occasion for Day 3 of testing. During this time period, subjects
were fed the pre-prepared standardized meals and fluids at set
times of day. Subjects were asked to consume all foods on their
tray within a specified period of time. Following completion of the
meal, the research dietician retrieved the food trays and kept all
unfinished foods for analyses. Following the initial two-day study,
the subjects were admitted again for another half day of testing
(Day 3). All subjects were fed the same standardized meals as those
served on Day 1 and 2 at the same time of day, blood and urine
samples were drawn at the same time (see Study Design in Table 1)
and then handled similarly by the same person (S.H.), frozen at
280uC within 30 min. All sample collection tubes were from a
single batch and plasma was separated from whole blood before
freezing. Samples were shipped on dry ice to the analytical
laboratories for metabolomics analysis.
Non-targeted metabolomic analysis
For these studies, the chemical identification of only a subset of
metabolites was performed, since compound identity is not
required for evaluating pure metabolome variability. For logistical
reasons, the urine and blood analyses were performed in two
distinct state-of-the art laboratories; however, the experimental
design was identical for the entire course of the metabolomics
analyses.
Plasma sample preparation. Frozen plasma samples were
thawed at room temperature, and a 10-mL aliquot was removed
from each tube and transferred to a polypropylene microcen-
trifuge tube containing 90 mL of HPLC-grade methanol. These
mixtures were centrifuged at 10,0006g and 4uC for 10 minutes,
and 50 mL of each supernatant and 50 mL of Milli-Q water were
transferred to an amber autosampler vial containing a low volume
glass insert. The samples were organized based on a pre-
determined order of analysis, including a series of technical
replicates analyzed with each 54-vial tray of plasma extracts.
Plasma metabolite profiling. Plasma metabolites were
profiled using liquid chromatography/time-of-flight mass spec-
trometry (LC/TOF-MS) using a LCT Premier mass spectrometer
(Waters Corp., Milford, MA) that was coupled to three LC-20AD
pumps, column oven, and a SIL-5000 autosampler (Shimadzu,
Columbia, MD) equipped with a six-tray chilled autosampler stack
that was held at 10uC. Aliquots (10 mL) of each extract were
injected, and metabolites were separated using an Ascentis Express
C18 column (2.1650 mm; 2.7 mm particles; Sigma-Aldrich, St.
Louis, MO) and linear gradient elution based on solvents A
(0.15% aqueous formic acid), B (acetonitrile/methanol 1:1 v/v),
and C (acetone) as follows (A/B/C): 0–1.0 min (95/5/0), 1–3 min
(program to 40/60/0). 3–9 min (program to 0/100/0), hold until
11 min. At 11 min, the solvent was programmed to 100% C at
12 min to wash the column and this composition was held until
13.5 min, after which the solvent was returned to the initial
condition. Total flow rate was 0.40 mL/min, and the column was
held at 50uC. Mass spectra were acquired using electrospray
ionization (data were acquired in both positive and negative modes
separately), over m/z 50–1500. Quasi-simultaneous acquisition of
mass spectra was performed in four separate acquisition functions
using W-mode ion optics (mass resolution of 10,000), transit lens
voltage settings of 10, 30, 50, and 75 volts, and spectrum
acquisition time of 0.15 seconds per function. Only data acquired
under the first acquisition function were processed during this
study, but the higher energy functions yielded fragment ions useful
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for metabolite annotation [16], and this process was aided through
manual comparison of molecular and fragment masses with entries
in the Human Metabolome Database [17].
LC/TOF-MS data were processed using Waters MarkerLynx
software, which performs peak detection, integration, and
retention time alignment. Processed results were exported as
unscaled peak areas, organized by chromatographic retention time
and m/z (mass) value, into a Microsoft Excel spreadsheet.
Urine sample preparation. Urine sample aliquots kept at
280uC were thawed on ice and 150 mL of ice-cold methanol was
added to each sample [18]. The volumes of the urine samples were
normalized to osmolality. Samples were vortexed vigorously then
placed at 220uC for 1 hour in a pre-chilled tube rack. Samples
were then vortexed briefly and microcentrifuged for 10 minutes at
max speed. Supernatants were removed and transferred to a clean
microcentrifuge tube while leaving pellet undisrupted. Superna-
tant was microcentrifuged again at max speed and once again
transferred into a clean microcentrifuge tube. Samples were then
subjected to SpinVac to dryness with heating to 60uC or less for
approximately 3 hours. Samples were then resuspended in 50 mL
of water: acetonitrile (98:2) and centrifuged for 5 minutes in
microcentrifuge at max speed and transferred to plastic auto-
sampler tube and capped. Samples were stored at 4uC if used
within 1–2 days otherwise kept at 220uC.
Urine metabolite profiling. HPLC-MS analysis was per-
formed on an Agilent 1200 Series Autosampler coupled to an
Agilent 6530 Accurate Mass Q-TOF with an Agilent Jet Stream
electrospray ionization source. Analytes were separated on a
Phenomenex Kinetex 2.6 mm XB-C18 100A reverse phase
column using 0.1% formic acid in water (A) and 0.1% formic
acid in acetonitrile (B). The gradient was run at 0.35 ml/minute
and consisted of an isocratic separation for 0.5 minutes of 2% B,
and then B was increased at a linear rate to 70% at 13 minutes,
95% at 14 minutes, held at 95% until 15 minutes, then re-
equilibrated for 3 minutes with 2%B at 0.5 ml/min. The mass
spectrometer was set to measure ions over m/z 60–1000 in positive
ionization mode at a rate of 6 spectra per second. Automatic MS/
MS was enabled with a scan rate of 6 spectra per second and a
range of m/z 25–1000. MS/MS active exclusion was enabled and
collision energy was set to range from 20–70 eV. Agilent Mass
Hunter Qualitative Analysis was used to export raw peak areas
from the RP-HPLC-QToF using the ‘‘find by molecule’’ feature.
The data were then exported as a CEF file to Agilent Mass Profiler
Professional for peak alignment. Retention time window was set to
+/20.5 min and there was no minimum area cutoff. This aligned
peak list was then exported for recursive analysis using the ‘‘export
for recursion’’ function by Agilent Mass Profiler Professional.
Recursive analysis was then performed, which is a more targeted
approach to fill in the missing values, using the ‘‘find by formula’’
feature in Agilent Mass Hunter Qualitative analysis with known
retention times. The peaks were then re-exported to Agilent Mass
Profiler Professional and re-aligned. The filter by frequency
function was used and set to 60% of all samples. Raw data were
then exported to a CSV file and put into Microsoft Excel. A
compound database was made using MS/MS matches from
NIST, ReSpect, LipidBlast, Metlin AM, and manual search by
accurate mass and MS/MS features found in samples. Retention
times and formulas were recorded and put into the database. The
‘‘find by formula’’ feature in Agilent Mass Hunter Qualitative
Analysis was used with retention time matching +/20.3 minutes.
Compound peaks were then exported as CEF files to Mass Profiler
Professional and aligned. Raw data were then exported to
Microsoft Excel.
Statistical Analysis
Six plates were required to analyze all samples using the LC-MS
equipment for both urine and plasma; placement of samples on
each plate was randomly determined. To investigate batch effects
potentially resulting from the need to use six plates, we randomly
selected 3 control and 3 ADPKD subjects’ fasting samples
collected on Day 2 (urine and blood analyzed separately) to serve
as ‘‘reference’’ quality control samples; each of these reference
samples was analyzed on every plate analyzed on the LC-MS
platforms. Batch effects and within-lab reproducibility were
evaluated using the repeated measurements of the six reference
samples included on all plates.
A total of 782 urinary metabolites and 873 blood metabolites
were identified in at least one sample. Among them, only the 294
Table 1. Study Design: Times of urine and blood collection and meals.
Day 1 Day 2 Day 3
+1 hour (Fasting Pre Breakfast) +1 hour (Fasting Pre Breakfast) +1 hour (Fasting Pre Breakfast)
08:30 08:30 08:30
09:00 Meal 09:00 Meal 09:00 Meal
+3 hour (Post Breakfast) +3 hour (Post Breakfast) +3 hour (Post Breakfast)
11:00 11:00 11:00
12:00 Meal
+7 hour (Post Lunch)
15:00
+9 hour (Pre Dinner)
17:00
17:30 Meal
+11 hour (Post Dinner)
19:30
+14 hour (Late Night)
21:30
doi:10.1371/journal.pone.0086223.t001
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urinary metabolites and 121 blood metabolites were detected in all
296 samples (26 subjects610 time points plus 36 reference
samples) analyzed. Because this study focused on variability and
imputing missing values could artificially affect the variability, we
limited our analyses to the 294 urinary metabolites and 121
plasma metabolites that were detected in all samples to avoid the
bias that could be induced by imputation. For normalization, the
intensity values for each sample run were summed, and then the
median value of the sums across all samples was determined. The
intensity values of each sample were scaled such that the sum of
the scaled intensities equaled the median value. Thus, the sum of
the scaled intensities was the same for all samples. Normalized
intensity values were then log2 transformed to meet assumptions of
normality and homoscedasticity of statistical tests and reduce the
influence of extreme values.
We conducted variance component analyses (VCA) to estimate
the relative contributions of the temporal factors (meals, time of
day, and day-to-day effects) to the total variation in metabolite
intensities. To assess meal effects, we restricted the analysis to
samples collected before and after breakfast (hours +1 and +3;
Table 1) and before and after dinner (hours +9 and +11). Meal
effects were separately analyzed for each day. For day-to-day
effects, we used samples repeatedly collected over 3 days at each
time point before and after breakfast (i.e., at hour +1 and hour +3
separately). Finally, time of day effects were evaluated using all
samples collected on Day 1 with time of day modeled as a
categorical variable. A VCA was conducted for each metabolite.
Specifically, the intensity level of the each metabolite, Yi, were
modeled as follows: Yi = mi+TempFactori+Subjecti+ei, where TempFac-
tor,N(0, s2F) is the effect of each temporal factor (meal, time-of-
day, and day-to-day) variation among measurement units;
Subject,N(0, s2S) is the effect of subject variation among
measurement units; and ei,N(0, s2R) is the residual error, i.e.,
variation caused by factors other than the variables included in the
model. All factors were modeled as random effects. Given the
small sample size of the study population relative to the number of
variables, we did not evaluate age, gender, race or ADPKD effects.
Instead, all subject characteristics (age, gender, race, PKD status,
etc.) were encompassed by the ‘‘subject’’ component to quantify
the subject-to-subject variability. For each metabolite, variance
components were estimated by the relative proportion of the total
variation of the metabolite contributed by each temporal factor
(meal, time-of-day, and day-to-day), subject and residual error.
The total variance was assumed to be the sum of three
components: VARTot = VARTempFactor+VARSubject+VARResidual. The rel-
ative proportion of each source of variation was calculated as a
ratio of the variance estimate to the sum of all three variance
estimates. For example, pMeal~
VARMeal
VARTot
calculates the propor-
tion of the temporal factor variation attributed to meal and
pRe sidual~
VARResidual
VARTot
calculates the proportion of variation due
to unaccounted variation (residual error).
We also performed differential analyses to identify individual
metabolites whose intensities were altered significantly in relation
to the temporal factors. We used a mixed effects analysis of
variance (ANOVA) for the differential analyses. The intensity of
each metabolite was modeled as a function of the temporal factor
of interest (meal, time-of-day, and day-to-day). A random subject
effect was included to account for the correlation of repeated
measurements from the same subject. False discovery rates (FDRs)
were calculated to adjust for multiple testing and a FDR rate
,0.05 was considered significant. Variance component and
differential analyses were conducted with Proc Mixed in SAS
version 9.2 (SAS Institute, Cary, NC).
Results
Subject population and protocol conduct
Subjects were studied on the inpatient unit of the Clinical
Research Network of the Atlanta Clinical and Translational
Institute between March and October, 2010. Characteristics of the
subjects are provided in Table S1. Of note these were relatively
young (33+/210.9 years), non-obese (BMI 24.3+/23.3 m2)
subjects with 12 men and 14 women (58% Caucasian). Mean
eGFR based on the MDRD formula was 99+/217 mls/min/
1.73 m2. Women were studied between days 5–13 of their
menstrual cycle. All breakfasts were served between 8:57 am
and 9:35 am, all lunches between 12:00 and 12:05, and all dinners
between 17:29 and 17:55 (Table 1). One hundred percent of 123/
130 meals were consumed with the remaining seven meals being
completed by more than 91% of gms provided. Average measured
dietary intake was 2620+/2560 kcal/kg/day and protein intake
was 1.04+/20.3 gm/kg/day.
Reproducibility of metabolomics data: batch effects
The rationale for using both normal, healthy individuals as well
as an identical size cohort of subjects with a chronic stable kidney
disease (ADPKD) with normal kidney function was to be able to
ultimately extend our findings to biomarker studies of this and
other diseases. However, the subsequent data were also evaluated
separately for these two cohorts and showed qualitatively similar
results (File S1), confirming the utility of our analysis for both
normal and diseased states. The metabolites analyzed were limited
to those present in all samples, as our study was not designed to
discover metabolite biomarkers for PKD.
All urine and plasma samples were separately processed from
the participants by LC/TOF-MS in one equipment run (albeit
there were separate plates for each run as necessitated by several
day operation, see below) for each biofluid (Files S2a [plasma] and
S2b [urine], uploaded into MetaboLights). However, because of
the high number of samples (296) and the consequent necessity to
process the samples in several batches (i.e. plates), it was
considered possible that this introduced variability into the data.
Thus, batch effects on the metabolome (defined as the systematic
error introduced by time and plate-dependent variations prior to
specific metabolome variability analyses) were evaluated by
including six reference biofluid samples on each plate. For the
assessment of batch effects, intensity values were log2 transformed
but not normalized, since normalization could preclude discovery
of systematic shifts between plates. Boxplots of the intensity values
of each reference sample on each plate did not reveal any large,
systematic pattern in the magnitude or distribution of intensities
across batches (Figs. S1, S2). Scatter plots for each reference
sample showed high correlations between intensities measured on
different plates (data not shown). We calculated the coefficient of
variation (SD/mean) across the six plates for each metabolite in
each reference sample to provide a direct quantitative measure of
technical between-batch variability. The median CV values of the
6 samples ranged from 0.012 to 0.097 and 0.070 to 0.110 in urine
and blood, respectively (Fig. S3, S4). These low CV values
demonstrate adequate technical reproducibility of sample analyses
across all of the six plates used for the LC/TOF-MS analyses.
Further, the results demonstrate that systematic batch effects were
minimal and that, at a gross level, the LC/TOF-MS procedures
that required running multiple plates for both analyses (plasma
and urine) yielded reproducible results.
Metabolome Variability in Urine and Plasma
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Source and proportion of variation attributable to each
effect
For a metabolite biomarker, or suite of metabolite markers, to
be clinically useful, it is critical to define sources of variation of the
metabolome that could result in changes in the metabolite
concentration and thereby confound the clinical interpretation.
For example, if the metabolite signal changes as a function of meal
or collection times, specific sample procurement procedures will
need to be implemented in order to eliminate variability due to
influences other than the factor of interest (e.g. disease state), and
to avoid bias which can occur during the process of specimen
collection. In this study, we focused on assessing the influence on
the metabolome of environmental and physiological factors related
to meals and time of day of sample collection, because these are
clinically relevant parameters with respect to sample selection and
collection.
Using VCA, we quantified the relative amount of variation in
the metabolomic data arising from the following clinically
important factors: mealtime, time-of-day, day-to-day, subject-to-
subject, and residual variability. It is important to keep in mind
that we are looking at the relative amount of variability attributed to
each source of variance proportional to the total variability in the
data (total variability = 100%), since the absolute quantitation of
variability varies by experiment and mass spectrometer used for
each run. The largest percentage source of variability in this study
was attributable to ‘‘residual variability,’’ which accounted for
.50% of the observed variation in intensity for most of the
metabolites (Figs. 1 and 2). This form of variability is a result of
technical variability (i.e., the multiple step process of sample
preparation and LC/TOF-MS analysis) and possibly experimental
variability (i.e., sample collection, although this was very unlikely
in this study due to the high consistency in the collection
procedures) rather than intrinsic biological variability. Although
less than technical and experimental variability, between subject
variability, which represents intrinsic biological properties of the
samples (i.e., genetic or metabolic differences among subjects), was
also large across the subject population and may have been in part
related to gender and ethnic heterogeneity and general health
status among the human subjects. This data suggest that
minimizing technical variability is equally important to increasing
a sample size to yield significant findings for a clinically applicable
human biomarker study.
To evaluate the effect of meals on metabolome variability, we
obtained blood plasma and urine from the subjects under tightly
controlled conditions in an inpatient clinical research facility using
prepared meals with standardized components for equivalent
carbohydrate and calorie intake normalized to BMI. Samples were
obtained at fasting (+1 hr) and 1 hour post-breakfast (+3 hr) as
well as 1 hour before (+9 hr) and after dinner (+11 hr; Table 1).
Repeated samples taken from the same subject before and after the
morning and evening meals showed a surprisingly low degree of
variation attributable to meals as compared to other factors. In
addition, variation attributable to meals was higher in urine than
in blood (‘‘meal’’ bars in Fig. 1). Interestingly, for the majority of
the metabolites, the meal effects on the metabolome variability
were more pronounced in the morning than in the evening meal,
indicating that the impact of eating after the approximately
8 hours fast and sleep overnight on degree of changes in the
metabolome was more evident than that of eating after a short fast
of 4 hours during an awake and active period (compare ‘‘Day 1-,
2-, 3-Breakfast’’ with ‘‘Day 1-Dinner’’ in Fig. 1).
The between day comparison of each fasting to post-breakfast
sample over 3 days demonstrated that the variability attributed to
meals was relatively consistent in both urine and blood (Fig. 1),
indicating reasonable inter-day reproducibility of the metabolite
intensity, an important consideration for reproducibility in any
future metabolomics-based biomarker test. To further assess inter-
day variability as a function of meals, the coefficient of variation
(CV) was calculated for each metabolite across three days for
fasting samples and post-breakfast samples. The distributions of
the CVs were very similar for fasting and post-breakfast samples
(Fig. S5). Thus, both fasting and post-breakfast meal samples had
similar inter-day reproducibility and inter-day variability was not
prone to variability due to meals.
The estimated proportions of total variability attributed to each
temporal factor across all metabolites are summarized in Table 2.
The percentage of the variance accounted for by the morning
meal varied among urinary metabolites, ranging from 0 to 84.6%
with an average of 7.6% on Day 1, from 0 to 86.1% with an
average of 8.7% on Day 2, and from 0 to 67.6% with an average
of 6.2% on Day 3. The evening meal accounted for less variation
than the breakfast meal and ranged from 0 to 44.2% with an
average of 3.6% on Day 1. Consistent with previously discussed
biofluid differences, the meal effects were nearly half or lower in
blood as compared to urine, with a maximum percentage of
36.3% on Day 2.
Metabolite intensities showed some variability as a result of time
of day, which was partially confounded by meal effects (Fig. 2) and
was also considerably lower in blood than in urine. The
correlations in metabolite intensities were calculated between
each pair of measurements at two time points on Day 1. In urine,
the correlations between repeated measurements were larger for
nearby times than far-apart times (Table 3), however, this did not
occur with the blood metabolome. The correlation coefficients
were constant regardless of the length of time interval between the
measurements in blood (Table 4), demonstrating that the blood
metabolome was less influenced by meal or time of day of sample
collection than was the urine metabolome. We also observed that
the intraday temporal patterns of metabolite intensity change over
time varied by individual subject and by metabolite (Fig. S6),
indicating the presence of complex heterogeneity of metabolite
changes among subjects. Figure 3 illustrates the temporal patterns
of variability of specific blood metabolites selected as representa-
tive of the full range of degree of variability, as determined by CVs
(Table S2), from highly variable to most stable (Table 5).
Factors most influential to changes in metabolite
intensities
To further understand the features that modify metabolite
intensities among subjects, we conducted differential analyses to
identify which factor(s) significantly influence metabolite intensi-
ties. The VCA characterized the relative contribution of each
temporal factor but did not address the actual magnitude of the
effect of each factor and its significance. The effects of meals and
time-of-day were significant for a large number of urinary
metabolites but day-to-day variation was minimal with only few
metabolites differing significantly across days especially in blood
(Table 6). Thus, we found that meals were a significant source of
variability in some urine metabolites, but that meals had minimal
to no influence on blood metabolites. In general, day effects (as
assessed on three days) were not statistically significant, which
confirmed the minimal day-to-day variability we observed in the
VCA results. However, time-of-day appeared to be a significant
factor in urine while its effect on blood metabolome was minimal.
The time-of-day effects were partially attributable to meal effects.
Taken together, meals and time-of-day appear to be important
factors to consider for urinary metabolites and to a lesser degree
for blood metabolites.
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Figure 1. Variance components analysis in urine (A) and blood (B) metabolites for meal effects. Distribution of the relative proportion of
total variance explained by each factor (meal, subject, residual) across all metabolites. Data of Hours +1 (pre-) and +3 (post- breakfast) and Hours +9
(pre-) and +11 (post-dinner) in each day were used in the analysis to estimate the proportion of variation attributable to meal effects for each of
individual metabolites separately.
doi:10.1371/journal.pone.0086223.g001
Figure 2. Variance components analysis in urine (A) and blood (B) metabolites for time of day effects. Distribution of the relative
proportion of total variance explained by each factor (time of day in hour, subject, residual) across all metabolites. For time of day effects, data
measured at hour +1, +3, +7, +9, +11, and +14 on Day 1 were used in the analysis to estimate the proportion of variation attributable to time of day
effects for each of individual metabolites separately.
doi:10.1371/journal.pone.0086223.g002
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Discussion
While extant studies support the contention that metabolomics
has enormous potential to provide insight into physiological as well
as pathophysiological processes in human biology with tremen-
dous clinical applicability, the limitations of this technique
especially with respect to clinical translation, as with other omics
technologies [5], are conceivably manifold. Most such limitations
are related to the fact that metabolic processes, more than genes
and proteins, are by nature influenced by exogenous as well as
endogenous stimuli, for example: meals, medications, menstrual
cycles, and circadian rhythms [8,19–23]. While several studies in
humans and animals evaluated the influence of these factors on the
metabolome, we could find no published studies performed on
human subjects in a tightly controlled dietary environment, as
would occur in an inpatient clinical research center, such that
highly accurate conclusions can be drawn. The current study of
plasma and urine metabolome variability was undertaken in a
setting of extreme consistency of human subjects in such an
inpatient facility in the time scale of hours and days. While this
extreme of consistency would of course not occur in the everyday
clinical setting, it is necessary to perform this type of study to draw
conclusions about which factors of the external environment,
particularly parameters related to sample collection, contribute to
human metabolome variability and how the metabolome is altered
as a result of these factors.
The observed variability in our data can be explained by, in
general terms, (1) biological and (2) technical variation. Biological
variation reflects the intrinsic properties of a biological system,
such as genetic background, gender, age, and state of health. In
contrast, technical variability represents non-biological variability
such as sampling or technical issues, which often cannot be
explicitly pinpointed. Sources of such technical variation include,
but are not limited to, measurement errors associated with sample
collection (unlikely due to the extreme consistency in this process),
sample preparation for chemical analysis, sample injection time
and order in the mass spectrometer, chromatographic separation,
LC-MS data acquisition and instrument drift, and data processing.
While we found minimal systemic inconsistency among batches
run on the analytical equipment, there was a large component of
residual variability, which resulted from other technical sources
other than temporal and mealtime parameters, of the metabolome
in all samples. While residual variability will never be completely
eliminated, the relatively large proportion of the variability
attributed to residual variation (in relation to biological variation),
even in such a tightly controlled environment and state-of-the-art
analytical laboratories as were used in this study, emphasizes the
importance of using standardized and consistent methods of
collecting, processing and analyzing samples to minimize as much
as possible this source of variation. On the other hand, mealtime
variability was relatively low, particularly in blood as compared to
urine, indicating high utility of metabolomics for biomarker
discovery.
Table 2. Proportion (mean 6 SD) of variance attributable to each source of variation relative to the total variation in metabolite
intensity across all metabolites.
Within-Day Variability
Between-Day
Variability
Source of
variance Meal effects
Time of day
effects Day-to-Day effects
Day 1 Day 1 Day 2 Day 3 Day 1 Days 1–3
(+1 &+3) (+9 &+11) (+1 &+3) (+1 &+3) (hours +1 to +14) (only +1 hour)
Meal 0.07660.14 0.03660.08 0.08760.15 0.06260.13 0.08460.13 0.02360.039
Urine Patient 0.39660.22 0.30660.21 0.22860.21 0.2860.24 0.24960.19 0.30660.17
Residuals 0.52860.24 0.65860.22 0.68560.23 0.65860.25 0.66760.22 0.67060.18
Meal 0.02560.04 0.00760.03 0.04160.07 0.00960.02 0.02760.04 0.0160.02
Blood Patient 0.3560.28 0.3760.29 0.3660.24 0.36260.29 0.32260.26 0.28760.24
Residuals 0.62560.27 0.62360.29 0.59960.23 0.62860.29 0.65160.26 0.70360.24
doi:10.1371/journal.pone.0086223.t002
Table 3. Pearson’s correlation coefficients of urinary
metabolite intensities between hours of collection on Day 1.
Hour 1 Hour 3 Hour 7 Hour 9 Hour 11 Hour 14
Hour 1 1.00 0.81 0.74 0.74 0.73 0.73
Hour 3 0.81 1.00 0.82 0.80 0.81 0.76
Hour 7 0.74 0.82 1.00 0.84 0.81 0.82
Hour 9 0.74 0.80 0.84 1.00 0.81 0.82
Hour 11 0.73 0.81 0.81 0.81 1.00 0.83
Hour 14 0.73 0.76 0.82 0.82 0.83 1.00
doi:10.1371/journal.pone.0086223.t003
Table 4. Pearson’s correlation coefficients of plasma
metabolite intensities between hours of collection on Day 1.
Hour 1 Hour 3 Hour 7 Hour 9 Hour 11 Hour 14
Hour 1 1.00 0.93 0.93 0.93 0.93 0.94
Hour 3 0.93 1.00 0.91 0.92 0.91 0.94
Hour 7 0.93 0.91 1.00 0.94 0.94 0.93
Hour 9 0.93 0.92 0.94 1.00 0.95 0.93
Hour 11 0.93 0.91 0.94 0.95 1.00 0.93
Hour 14 0.94 0.94 0.93 0.93 0.93 1.00
doi:10.1371/journal.pone.0086223.t004
Metabolome Variability in Urine and Plasma
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e86223
It is important to note that this study was conducted to
specifically assess variability in the metabolome as a function of
temporal and mealtime parameters and not to identify metabo-
lomic changes associated with any particular disease state or
specific biologic parameter. Thus, we utilized a mixed subject pool
of healthy subjects with ADPKD as well as healthy volunteers to
Figure 3. Temporal variability of selected metabolites. Variability in intensity values (log2 transformed) of selected metabolites in healthy
volunteers is graphed as a function of indicated time (see Table S2). Each colored line represents one subject.
doi:10.1371/journal.pone.0086223.g003
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broaden our results to the general population; however the
subject-to-subject variation due to biological differences among
subjects (which included but was not limited to ADPKD state) was
partitioned separately as a ‘‘subject’’ random effect component in
the VCA. It should also be pointed out that the study was not
powered to specifically dissect variability attributable to each of
intrinsic biological properties, such as genetic mutation of
ADPKD, gender, age, race, while controlling for each other’s
confounding effects. Despite of the lack of statistical power, we
evaluated variability separately and show that the individuals with
ADPKD showed qualitatively similar results to the disease-free
healthy subjects as well as the combined cohort with respect to the
temporal variability, suggesting excellent applicability of metabo-
lomics to disease biomarker studies.
Interestingly, urine showed more biological variability than
blood, emphasizing the need for more urine samples as compared
to blood samples in a well designed metabolomics biomarker
study, consistent with a previous animal study from our laboratory
[24]. In addition, both blood and urine variability was higher after
the morning meal than the evening meal, perhaps reflecting a
more pronounced influence on homeostasis when food is
consumed after an 8 hr fast as compared to a shorter inter-meal
time interval during daytime which may be due to circadian
influences independent of meals changes the metabolome. It was
also evident that there were a considerably higher number of
significantly changed metabolites in urine as compared to blood,
with the highest number being a function of time-of-day and
mealtime. It was also apparent that there was less variation after
the evening meal than the morning, indicating that post-breakfast
sampling should be avoided. These data stress the need to be
consistent in collection times, and that it may be best to consider
fasting samples (which includes mealtimes) when evaluating the
urinary metabolome in particular.
Other studies have evaluated the effects of dietary interventions
on the human metabolome. In one study, a cohort of 10 healthy
volunteers was admitted to a clinical research center for 2 wk of
dietary standardization, and urine and plasma metabolomes were
measured daily by NMR spectroscopy [7]. These data showed that
a standardized diet that lasts a single day is likely sufficient to
provide all of the normalization that can be achieved in the human
metabolome, and is therefore consistent with our findings of high
day-to-day reproducibility. However, a separate study of urine
metabolomics in healthy subjects [25] showed a trend towards
reduced inter- and intra-individual variation during 3 days of diet
standardization. In another study [26], the effect of multiple
interventions on metabolomic parameters were evaluated; this
study demonstrated that such challenges (extended fasting, glucose
and lipid tolerance tests, controlled meals, physical exercise, and
physiological stress) increase metabolite variability between
volunteers, allowing discrete metabotypes to be identified that
would not be seen in normal fasting conditions. As far as
examination of the effects of a single dietary intervention on the
metabolome, another group in several studies evaluated the effect
of the urine metabolome after a single intake of cocoa and found
significant changes at 24 hours, inferring that the strategies which
they used can dissect the complex relations between the
consumption of phytochemicals and their expected effects on
human health [27,28]. Although it was not the purpose of this
study, we have shown that for example that glucose and other
sugars as well as phospholipids are changed in the post-prandial
state (Table S2). Furthermore, citric acid was found to be relatively
sensitive to meal difference compared to other metabolites
(Table 5). Thus it is important to standardize meals when studying
TCA cycle involved diseases.
While the urinary metabolome exhibited considerablly more
biological variability than blood in the current study, others have
also evaluated the urine metabolome with respect to gender, age,
and diet. One group found that metabolites related to mitochon-
drial energy metabolism helped differentiate gender and age, while
dietary components and circadian rhythm metabolites were
related to time of day [19]. Another group also used NMR-based
techniques to generate models differentiating subjects according to
gender and age [29], and another showed that the urine
metabolome, in contrast to that in the plasma and saliva, can
reflect acute dietary intake [20]. However, none of these studies
evaluated relative sources of varbiability; this is an unique aspect of
our work and is very germane to clinical translation of any
metabolomics study.
There are several studies, performed over a much longer time
frame than the current study, that confirm the existence of a stable
part of the metabolome that appears in the urine and which seems
to be specific to the individual subject. Bernini et al, in a study for
which the time scale was years rather than hours and days as we
have evaluated, showed that an invariate part of the metabolome
was stable over this long period [9]. Assfalg et al also demonstrated
an invariate portion of the metabolome characteristic of each
person in urine samples taken over a period of 3 months [10].
However, while consistent with our findings, neither of these
studies reported hourly or daily changes, or at specific changes as a
function of mealtimes in a controlled environment. Heinzmann et
al [11] performed an exhaustive study evaluating the human
Table 5. Coefficients of variation for blood metabolites
representing the full range of variability.
Metabolite Meala Hourb Dayc
Glucosylceramide 0.1370 0.1352 0.1246
Glucose-6-Phosphate 0.1065 0.1253 0.1099
Citric acid 0.1017 0.0902 0.0848
Cholesterol 0.0766 0.0766 0.0723
Palmitic acid 0.0513 0.0497 0.0496
aMeal CVs were calculated using pre and post breakfast samples from each day.
bHour CVs were calculated using all values from Day 1.
cDay CVs were calculated pre-breakfast values from each day.
doi:10.1371/journal.pone.0086223.t005
Table 6. Number and percentage (%) of significantly
changed metabolites (FDR,0.05) in blood and urine by three
factors (meal, day, hour).
Urine Blood
Factor Number (%) Number (%)
Meal
Day 1 (+1 &+3) 67 (23) 0
Day 1 (+9 &+11) 20 (7) 0
Day 2 (+1 &+3) 34 (11) 7 (6)
Day 3 (+1 &+3) 39 (13) 1 (0.8)
Hour 135 (46) 11 (9)
Day 2 (0.7) 1 (0.8)
There were a total of 294 metabolites identified in urine and 121 in blood.
doi:10.1371/journal.pone.0086223.t006
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urinary metabolome in 7 individuals in a 7-day controlled diet,
although unlike our study these individuals were not admitted to a
clinical study center. Consistent with our study, these investigators
found marked differences in the individual metabolomes such that
each individual possessed his/her own ‘‘metabolic phenotype’’; the
authors made the suggestion, based on their data, that individuals
should serve as their own controls. In another study comparing
urine, plasma, and saliva on a standard diet [20], it was found that
urine was more sensitive in detecting dietary differences than the
other biofluids, consistent with our findings in the present study.
In summary, our study utilizing volunteer human subjects in a
tightly controlled environment provides for the first time a
framework in which to view the data obtained from a well
designed and consistently executed metabolomics experiment.
While the day-to-day variability was minimal, there are meal and
collection time effects to be considered, and these are more
pronounced in urine than blood. Given the ready availability of
LC-MS techniques in many universities, clinical and commercial
laboratories, and the accepted power of metabolomics for clinical
translational research, there will likely be many more studies using
this technique in the near future. While our study confirms the
utility of metabolomics for both blood and urine analysis for
discovery of disease targets and biomarkers, the data shown here
inject a cautionary note into the design of future metabolomics
studies, as has been highlighted in a recent study [5]. For example,
based on our data presented here, a well-designed study biofluid
metabolomics should have the following characteristics: (1) the
study should be designed to avoid systematic errors by minimizing
bias by controlling for extraneous variables such as meals or time
of day of sample collection; (2) the study should have broad
applicability (i.e., the results hold for more than the subjects tested
in a study); (3) the study should have sufficient statistical power to
test the effect of the parameter of interest (i.e. disease); (4) the study
should attempt to minimize technical variability by optimizing
analytical tools; and (5) it would be prudent to utilize fasting blood
samples, and, if such samples were not feasible, random pre-meal
samples obtained during midday would be preferable over post-
meal samples to minimize bias by extraneous variables. Keeping
these concepts in mind, in both design and interpretation of
metabolomics data, will enhance the already considerable utility of
this growing field.
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